Compare Recursion Pharmaceuticals Inc (RXRX) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vistra Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B), while Vistra Corp trades at $159.2 (market cap $52.41B). The key difference: Vistra Corp is far larger — about 24.5× Recursion Pharmaceuticals Inc's market cap, and Vistra Corp pays a 0.59% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Vistra Corp for 32 Days on average.
| RXRX | VST | |
|---|---|---|
Market Cap | $2.14B | $52.41B |
Volume | 30,789,535 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $6.79 | $210.85 |
52-Week Low | $2.84 | $134.71 |
Typical Hold Time | 22 Days | 32 Days |
Enterprise Value | $1.66B | $74.34B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Vistra Corp. (VST) trades at $166.72, up 3.88% today, with a bullish technical signal and strong analyst support. The stock shows robust profitability with a net income margin of 11.55% and ROE of 75.73%, though earnings have been mixed recently. Recent developments include a $4.2 billion US loan to boost nuclear power and a 20-year power deal with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.
Outlook is positive given strategic positioning in AI power infrastructure, but risks include earnings volatility and high valuation multiples. The consensus price target of $215.23 implies significant upside, supported by institutional interest and favorable sector trends. Investors should weigh growth prospects against execution risks and market sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
